Broadening the range of use cases for ivermectin - a review of the evidence.

Christian Kositz ORCID logo; John Bradley ORCID logo; Harry Hutchins ORCID logo; Anna Last ORCID logo; Umberto D'Alessandro ORCID logo; Michael Marks ORCID logo; (2021) Broadening the range of use cases for ivermectin - a review of the evidence. Transactions of the Royal Society of Tropical Medicine and Hygiene, 116 (3). pp. 201-212. ISSN 0035-9203 DOI: 10.1093/trstmh/trab114
Copy

Ivermectin is a broad-spectrum antiparasitic agent that interferes with glutamate-gated chloride channels found in invertebrates but not in vertebrate species. Mass drug administration (MDA) with ivermectin-based regimes has been a mainstay of elimination efforts targeting onchocerciasis and lymphatic filariasis for more than 3 decades. More recently, interest in the use of ivermectin to control other neglected tropical diseases (NTDs) such as soil-transmitted helminths and scabies has grown. Interest has been further stimulated by the fact that ivermectin displays endectocidal efficacy against various Anopheles species capable of transmitting malaria. Therefore there is growing interest in using ivermectin MDA as a tool that might aid in the control of both malaria and several NTDs. In this review we outline the evidence base to date on these emerging indications for ivermectin MDA with reference to clinical and public health data and discuss the rationale for evaluating the range of impacts of a malaria ivermectin MDA on other NTDs.



picture_as_pdf
Kositz_etal_2021-Broadening-the-range-of-use-cases.pdf
subject
Accepted Version
Available under Creative Commons: NC-ND 3.0

View Download